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counterpart entities in the United States and get on with the kinds of partner-
ships that can really advance the Canada-United States agenda on the innova-
tion front.
Thanks for listening.
DISCUSSION FOLLOWING THE REMARKS OF THEODORE C.
THEOFRASTOUS, DR. JOSEPH J. JANKOWSKI, AND MARK ROMOFF
MS. LUSSENBURG: Questions, I guess. Henry, do you have a question?
DR. KING: Okay. I wanted to ask Ted a question. You handle commer-
cialization of technology for the Cleveland Clinic. I believe I am right on
that. There are a lot of competitors forgetting that innovation that was devel-
oped by the doctor there.
What are the standards by which you determine who gets what and have
the standards worked out, in other words, in terms of your ultimate result?
MR. THEOFRASTOUS: Well, internally, the standard for distribution is
a function of institutional policy, and that is actually the same at Case as
well. At The Cleveland Clinic, the individual investigator receives 40 percent
of the net proceeds, and it is only net really of patent expenses from the
commercial application side.
In terms of the industry participants vying for the technology, it is really -
you would think it is a lot easier than it is, frankly, to get folks interested, to
get industry interested at an early stage, at least somewhat validated technol-
ogy. That is where, frankly, I can see a real benefit for something like the
OCE.
But it boils down to the best deal and what's going to be the best upside
for the institution. It becomes a very corporate type decision. What is going
to yield the best income? Which of the potential candidates is really going to
take this to market and put the highest level of investment into it?
Does that answer your question?
DR. KING: Yes. Has it worked?
MR. THEOFRASTOUS: I think so. You know, the problem with success
is creating our - and when we talk about conflicts of interest, we are kind of
dealing with the fact that it has been successful. And the genesis of those
Wall Street Journal articles was a very successful device that, you know, in
the interest of moving the innovation forward, you have people that ulti-
mately became very senior at this institution involved in and having a stake
in the commercialization. They consult. They help.
They really - you know, they believe in it. They think it is a great device
and God forbid it makes billions of dollars, and all of a sudden they are rich.
It makes people very uncomfortable that the white tower has people in it that
are really making a lot of money, but, in fact, our sort of proposition is that's
the way it was structured. The system was supposed to do that.
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So it has worked. We are just trying to figure out how we deal with our
success now.
MS. LUSSENBURG: I would have to go to Larry first if he still has a
hangover question.
Were your questions answered, or otherwise, I will move on.
MR. HERMAN: I just wanted to know, when Mark was talking about his
programs, I just wanted to quantify them. That was the point, and I think you
said you have a fund of $34 million dollars that you can leverage through
different partnerships to $75[million?], which I gather come from other pub-
lic agencies.
Is that correct?
MR. ROMOFF: Not always. In many cases, it is industry because in that
money, we count the partnerships that we put in place in order to enable
technology we develop. So if a company is putting in the $50,000 I talked
about, we are counting that $50,000 in the revenue we generate. So some of
it is tied by definition because it is for a specific project.
THE WITNESS: All right.
DR. KING: Michael?
MR. ROBINSON: Thank you.
A comment and two very short questions for Mark. This sounds sort of
like nothing new for Ontario. I remember a thing called the Ontario Technol-
ogy Fund, lots of high profile publicity, was Peterson's Government. Pat
Lagudwa was making speeches all over town, 50 percent Government and 50
percent corporations for commercialization.
It was kind of a joke because I did the contracts for the first two MDS,
SIEX and IMAX, both very successful. The Government having made the
announcement had no idea how to really put it together in detail. So, myself
and a Government lawyer who knew nothing about science, worked out the
contract and sold it to the Government.
My comment is: It sounds like you are a heck of a lot better organized
than the Peterson Government was and, of course, the Ontario Technology
Fund having had a few successes, I guess it was Bob Ray that killed it, so it
is good to see it back again in a new guise.
The question is this: Why is there no biotech in your five OCE portfolio
list here? I would have thought there is a lot going on there in Ontario, num-
ber one.
And number two, do you know if that ridiculous law that we had on the
books in Ontario is now gone, namely, that hospitals cannot own more than
ten percent of the business corporation? Because this has been a huge prob-
lem for commercializing, for example, the stuff that is coming out of U of T,
out of the Lunenfeld at Mt. Sinai, et cetera.
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And I worked on a major thing there for proteomics, and it just drove us
nuts. It just didn't make any sense at all. I was told that they were going to get
rid of it, but I wonder if it is gone.
MR. ROMOFF: Honestly, I don't know. To come to your second ques-
tion, I am not sure of that. Are you going to Bio in 2006 from here?
MR. ROBINSON: No.
MR. ROMOFF: Too bad because the premier is going to be there. You
should ask him. I don't know the answer. Someone else may know, I don't
know.
On the first one, as to why there is no center for biotechnology, I will give
you two answers, maybe three: One, the organization as it is currently fig-
ured is a reflection of what was there before the merger, so part of my chal-
lenge now is to think through how we redesign the corporation, whether we
reengineer it at all but how we might do that in order to tackle the issues of
the day. That is number one. That is the part - what you are seeing here is a
bit of a legacy.
The second thing is, although we do not have a center for biotechnology,
we spend an enormous amount of money and are engaged in a large number
of, in fact, life sciences and biotechnology projects. We are not into big
pharmaceuticals, but we are into a whole bunch of things. Photonics is
probably the one that has the most obvious number of activities involved
with the university hospitals network, for instance, in Ontario doing some
really interesting research that is all about life sciences.
Our materials and manufacturing folks are working with the University of
Toronto, tissue engineering projects, advanced polymers as vehicles for de-
livering medication internally; there are a whole bunch.
Of course, communications and IT guys are working on things, which you
might not consider in this field, but it is all about the security of medical re-
cords so we are, in fact, playing on this agenda, and the other thing we are
doing, which is very interesting, is we are engaged now in biotechnology and
the automotive sector, bringing those two together, bringing those two to-
gether, sort of like tech-tonic plates, ones you normally would not think
would come together, and maybe that's why you get some really interesting
innovation.
So we have got a bio-car project under way at the moment. So it is bring-
ing together developments in the industry sector and the auto sector to pro-
duce lighter, cheaper vehicles. So we are playing there. It is just not obvious
from the way in which we are structured.
The last thing I would say is that while its mandate is in a state of evolu-
tion, we are partnering close with MARS, and they are very much in the
agenda of life sciences but not really in the business at the moment of com-
mercializing technology.
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Where they are going to go over time is a bit unclear, but we are collabo-
rating with them on a number of things, and wherever they go, we are going
to be going there with them. So stay tuned with them on that front.
MS. LUSSENBURG: This gentleman over here had a question. I am
sorry; I do not know your name. Mike is coming.
MR. BARBER: That would be Doug Barber.
MS. LUSSENBURG: Doug Barber. Thank you.
MR. BARBER: I have a couple of questions for you, Mark, and just to
comment on Mark, years ago Mark threw fantastic parties for our customers
in Genim. It is my claim to fame. Genim has done as high as 38 percent of its
total business in Japan. So it was pretty successful, and we appreciated that,
and we are kind of glad we have got Mark back.
MR. ROMOFF: It took more than a party.
MR. BARBER: The question I have is do you see the OCE as a developer
of a culture of commerce? Also, I have a kind of a second question about
those 2,600 that you had last year, researchers: Does that include the stu-
dents?
MR. ROMOFF: It does include the students. That is the first thing. On the
other side, I do not know whether - we probably do not mean something
different when we say a culture of commerce and a culture of innovation. I
think if we just had the culture would be great. And I see OCE playing right
at the center of that agenda.
I mean, we are positioning ourselves to actually be the lead voice in On-
tario for that agenda but, more importantly, to be out there working in the
business community. But, you know, it is in a sense at the level what we are
calling the street, the people who actually really either make decisions or
influence decisions in order to really bring home the critical need for innova-
tion and technology development and people development, home grown in
Ontario and keep them in Ontario.
So my answer to that is, yes, and I know it is of huge interest for you, and
there is an area where we might just be able to reconnect, Doug, in a way that
will make a difference because I know it is a passion of yours.
MS. LUSSENBURG: Mr. Elmer. Is that right?
MR. ELMER: Yes.
MS. LUSSENBURG: All right.
MR. ELMER: I have two questions really: One is: Do you have an IP pol-
icy with respect to the allocation of IP rights with your collaborators, and if
you do not have a policy, I think you said something - I am not sure I heard
it correctly - but do you get involved in the allocation of those rights, and
how are those rights ultimately allocated?
MR. ROMOFF: Are you talking to Ted or talking to me?
MR. ELMER: No. I was talking to you.
[Vol. 32]
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MR. ROMOFF: In the case of our activities, it depends on who the play-
ers are because in Ontario most universities, university policy dictates that
the intellectual property rests with the university and in some cases with the
researcher.
So we will normally work with what the norms are, and it is up to indus-
try as to whether or not they are prepared to accept that arrangement. So, in
fact, there is no rule of the game on this, except that the folks from within the
Ontario Centers of Excellence come to the table for that negotiation with a
complete open mind because, again, we do not have a vested interest.
What I want to make sure happens is that when we sign what we call a re-
search collaboration agreement between a company and a researcher, what is
really critical is that they need to have addressed the issue of intellectual
property rights right up front at the beginning. That is the last thing you want
to be negotiating down the road, so that is how we play.
MS. LUSSENBURG: The gentleman up in the back.
MR. TSAI: I am James Tsai. Just a general question directed, I guess,
more towards Professor Theofrastous. You were talking about the pharma-
ceutical companies and the high costs that go into that.
Regarding world and intellectual property rights, I believe TRIPS article
66 said that the Government should give incentives to transfer the technology
to less developed countries, and this has been a big topic with antibacterial-
viral medication in Africa so on and so forth.
I was just wondering if any of the panelists can comment on what Gov-
ernmental mechanisms there are in terms of financing and providing incen-
tives to transfer technology or to develop.
MR. THEOFRASTOUS: I think that is an issue where you still sort of
have to stay tuned. Unfortunately, that is on the back end of product devel-
opment typically where all of those millions/billions of dollars have been
spent, and you know, the market forces of pricing even between North -
America - I'm sorry - between the United States and Canada are interesting,
the calculus of pricing in a market where there is otherwise no demand for a
product that is criminally needed; more where I have seen the debate going,
letting - treating it more as a market issue than something that is sort of fed-
erally mandated.
But with that said, I think you can expect the sort of general tenor of the
discussion somewhere between no and hell no, in part, because - and I think
this is the problem with that particular species of very forward looking policy
- ultimately, a corporation has an obligation to the shareholders, and the
shareholders don't benefit necessarily by giving away the assets that cost so
much money to create.
And I am not here to speak for capitalism generally, but I think that's the
dynamic that makes it difficult to be really aggressive in that area.
MS. LUSSENBURG: Dick?
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MR. CUNNINGHAM: I may have missed it in your earlier presentation,
but my experience with the European system of doing this sort of thing, one
of the criteria that has to be met is the determination that the funding could
not be obtained from private resources.
Just parenthetically, that is a terrible criterion for them because it hangs
under the countervailing authority and the WOD rules, but that's all right.
Is that a factor that you look at, and if so, is that something that you are
insidious about? Is it a real factor, or does it matter at all?
MR. ROMOFF: If you are asking in my case it does not matter at all. We
are judging every opportunity on the merit of the opportunity, and we also
have a peer review process for the research monies we get engaged in.
And it mirrors the ones Rich spoke about earlier, which it is compromised
of researchers who are looking at the merit of the science and the business
community, who are looking at the commercial potential of the innovation.
MR. THEOFRASTOUS: I would add on the United States side there are
actually, I think, several programs that are spiritually kindred with the OCE
program. In the State of Ohio, the Ohio Department of Development has
several programs, such as the third frontier program and the biomedical re-
search and technology transfer program. These programs ultimately allocate
ultimately many millions of dollars to early stage technology that is cannot
be financially backed. But, frankly, the grant process is one where you have
to demonstrate that if you get to the other end of it, it would be completely
financially viable.
And, at least, the rhetoric has been one around even a return on that in-
vestment from the stay, not that they get a direct return on the investment,
but they want to see that they are funding winners, and, in fact, they have
even kicked - the BRTT program, they have even kicked that out to the Na-
tional Academy of Sciences, to make sure that it is world class, it is going to
work. They do not want the money going into areas that are not a good, you
know, sort of financial bet.
In fact, the most recent program is even pushing state funds into the pri-
vate equity sector, providing matching funds for the private equity world to
go out and decide if these are good investments.
MS. LUSSENBURG: The gentleman up in the far right coroner.
MR. DORCHAK: Andy Dorchak.
MS. LUSSENBURG: Sure. Go ahead.
MR. DORCHAK: This is for Ted, and I will assume your approach is cor-
rect and still has potential for public relations nightmares like learning that
pharmaceutical companies pay for staff that will affect direct investing. Is
that a market issue or legal issue?
MR. M.m. BURG: Well, both the FDA and NIH have struggled with con-
flicts of interest themselves, and in essence, the approach has really sort of
been to disavow any of those relationships and shed them.
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I think the downside for anybody in this room that has ever been involved
in the process of taking a product through the Food and Drug Administration,
it is hard. It is expensive. It is a little bit opaque. And so to the extent you get
a person on the other end of that equation who is really trying to help you
and willing to spend some time, maybe even their own time to understand the
science well enough to get you through this maze, it is hugely valuable, and
the question is, you know, should there be some level of compensation for
that sort of off-the-clock help or not? I think the typical or the current tenor is
no. Does that answer your question?
DR. JANKOWSKI: I would weigh in two things there: It will be a market
force. At some point it hurts to have a Vioxx on the market if you have to
recall it, about $29 billion dollars worth of hurt, but secondly - and Case
actually hosted yesterday one of the real watchdogs of the pharmaceutical
industry, famous UCSF Professor named Dr. Nearri, and he is very anti-
pharmaceutical for lack of a better term, and you need that voice.
And you are right, it does garner public spectacle, and at the same time, if
you really look back and you say okay, greed and motivation such as this and
interactions with the FDA that are now even being policed but even prior to
that policing, look how good our drugs are in reality. How many Vioxxes do
you actually have?
How many deaths off drugs relative to the good do they bring? You
know, one out of 100 drugs may incite some sort of scandal, and it does not
mean you just let the system go, but I think it is more of a hype in media ac-
tivity than it really is a concern of the thee-tiered system that we discussed
today.
MR. THEOFRASTOUS: I guess I would add also to the extent the agen-
cies are trying to figure this out themselves, if they move too erratically, it is
going to have, it is going to have its own chilling effect on innovation. I
worked with a small company, a small spinal disk replacement company that
was looking at what they thought would be a $4 million-dollar clinical trial
with a ratcheting up with the safety concerns on the FDA. Now they are
looking at literally a $38 million-dollar clinical trial, and they don't have the
money. So this may actually not go forward in the United States
MS. LUSSENBURG: If I may comment, it seems to me when we talk
about conflict of interest that we have very different issues at very different
levels. The fact that someone in the FDA might receive financial reward for
approving a product or medicine is an inherent conflict of interest, quite dif-
ferent from when you started your remarks, and I suspect they were made to
stir the pot; that the motivation is not pristine when people are seeking to
make money out of the research they do.
It seems to me in our discussion about innovation and financing is that
there has to be a financial motivation. Some people are motivated purely
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about altruism and the good of human mankind, but, honestly, that is a very
small margin of our population.
Most. people work in research out of intellectual curiosity but also because
they have to put bread on the table, pay the mortgage, look after their kids, et
cetera, and that in my view is not necessarily a bad thing. That is what drives
our economy.
Entrepreneurship, which is something we seem to be lacking in Ontario -
and entrepreneurship and innovation seem to go hand in hand - is, in part,
because we are not sufficiently motivated by that dollar, and is it such a bad
thing as long as you have the checks and balances and perhaps transparency
as opposed to the opaqueness that you were referring to?
I guess like everyone I think it is a bad thing to have opaqueness in any
regulator or to give a financial reward to a regulator to approve your product
one way or another, directly or indirectly, but on the other end, before they
get there, surely to God we have to incent these people.
MR. THEOFRASTOUS: Yeah. I think the challenge is to the extent you
have got a previously fairly esoteric science, how are you going to take the
science forward without the investigator who is supposed to be the ultimate
objective scientific arbiter of the effectiveness and safety of this device, how
are you going to feel comfortable with the fact that they are going to get a
gigantic upside if they are successful?
I think it is manageable, and I think there are a number of ways it can be
handled, but the way it stands right now, we are all a little surprised that the
surgeon that is implanting a device, if it is ultimately successful, that they
will be extremely wealthy, and maybe we just should not be surprised.
DR. KING: We may have that for a topic next year.
MS. LUSSENBURG: Good.
DR. KING: I think we ought to cut it off.
MS. LUSSENBURG: Okay. Thank you, all. Thank you to our speakers.
I think you all know there were handouts, and they are on the table out-
side if you did not pick up the handout. I meant to mention that at the begin-
ning, but just to make sure that if you don't have a handout, please help your-
self.
Thanks very much to Joe, Mark, Ted, that was great.
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